Predictors of response to @entity1499 in early DMARD naive XXXX : results from the initial open-label phase of the SWEFOT trial.

@entity1 @entity627 @entity48584 @entity1500 @entity1499 @entity309 @entity617
OBJECTIVE: To identify predictors of response to @entity1499 ( @entity1500 ) in early @entity309 ( @entity309 ). METHODS: In the SWEFOT trial, @entity1 with @entity309 with symptom duration <1 year started @entity1500 monotherapy (20 mg/weekly) and 405/487 continued until the 3-4- month visit. The primary outcome measure was the DAS28-based European League against @entity627 (EULAR) response criteria. Multivariate logistic regression was used to study the association between response and the following baseline characteristics: gender, age, symptom duration, cigarette smoking habits, autoantibody status, Health Assessment Questionnaire (HAQ) score, concurrent @entity617 and treatment with non-steroidal anti-inflammatory drugs. Secondary response and remission measures were the American College of Rheumatology and the Simple Disease Activity Index and Clinical Disease Activity Index (SDAI/CDAI)-derived criteria. RESULTS: After 3-4 months of @entity1500 treatment, the frequency of EULAR good/moderate/no response was 34%/41%/25%, respectively. Parameters associated with a decreased likelihood of EULAR response were female gender (adjusted OR (adj OR) 0.50, 95% CI 0.31 to 0.81), symptom duration (adj OR per month increase 0.93, 95% CI 0.88 to 0.99), current smoking (adj OR 0.35, 95% CI 0.20 to 0.63) and higher @entity48584 (adj OR 0.56, 95% CI 0.40 to 0.80). Parameters associated with an increased likelihood of EULAR response were higher age (adj OR per 10-year increase 1.30, 95% CI 1.11 to 1.51) and @entity617 treatment (adj OR 2.84, 95% CI 1.43 to 5.63). The findings were similar when @entity1 on @entity617 were excluded and other response criteria tested, although current smoking was the only significant predictor using all response criteria, while HAQ was the only significant predictor of all the remission criteria used. A matrix showed up to ninefold differences between subgroups stratified by the main predictors. CONCLUSION: Current smoking, female sex, longer symptom duration and younger age predict a worse response to @entity1500 in @entity1 with new-onset @entity309 . TrialRegNo NCT00764725.
